Global Dravet Syndrome Market

Global Dravet Syndrome Market Size, Share, Growth Analysis, By Diagnosis(MRI, EEG), By Treatment and Management(Seizure medications, A ketogenic diet), By Type(Pharmaceutical Companies, Hospitals) - Industry Forecast 2024-2031


Report ID: SQMIG35A2815 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 92 | Figures: 67

Global Dravet Syndrome Market Competitive Landscape

The competitive environment of the global Dravet Syndrome market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor.

Top Player’s Company Profiles

  • SK Biopharmaceuticals
  • Biocodx
  • Upsher Smith Laboratories, LLC.
  • Encoded Therapeutics Inc.
  • GW Research Ltd.
  • UCB S.A.
  • Zogenix
  • Supernus Pharmaceuticals
  • Epygenix Therapeutics, Inc.,
  • Ovid Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Dravet Syndrome Market size was valued at USD 343.85 million in 2022 and is poised to grow from USD 376.17 million in 2023 to USD 771.84 million by 2031, growing at a CAGR of 9.4% in the forecast period (2024-2031).

The competitive environment of the global Dravet Syndrome market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. 'SK Biopharmaceuticals', 'Biocodx', 'Upsher Smith Laboratories, LLC.', 'Encoded Therapeutics Inc.', 'GW Research Ltd.', 'UCB S.A.', 'Zogenix', 'Supernus Pharmaceuticals', 'Epygenix Therapeutics, Inc.,', 'Ovid Therapeutics Inc.', 'Takeda Pharmaceutical Company Limited.'

Genetic mutations, especially SCN1A gene mutations, contribute significantly to the onset of Dravet syndrome in children, with approximately 80-90% of cases associated with mutations in this gene in this tissue specifically this related Advancement in genetic testing technology is expected to drive market revenue growth of testing methods. If applied, such as dual detection, deletion, mosaicism, and other methods a sophisticated diagnostic approach will play an important role in the accurate and efficient diagnosis of genetic abnormalities associated with Dravet syndrome.

Recent developments in regulatory approvals have played an important role in driving the Dravet Syndrome project forward. Notably, withdrawal from medications such as stiripentol (Diacomit) and Epidiolex have been extremely helpful in managing and treating the symptoms associated with the disorder. These regulatory veins mark important points landmark in dealing with the severe complications of Dravet syndrome. Furthermore, expectations of upcoming regulatory approvals, exemplified by Zogenix’s New Drug Application (NDA) submission for its clinical candidate ZX008 (Fintepla), are expected to fuel the rapid expansion of the market.

Market trends for specific industries highlight North America as the dominant region, exhibiting the greatest impact, followed by Europe and Asia Pacific Key market players are actively directing their efforts towards developing new drugs and therapies development, using various strategies to strengthen their market position. The competitive environment is characterized by a proactive approach in leading organizations, which engage in ongoing R&D activities to come up with innovative solutions. These strategic initiatives not only contribute to the expansion of the market but also enhance the competitive edge of the major competitors.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Dravet Syndrome Market

Product ID: SQMIG35A2815

$5,300
BUY NOW GET FREE SAMPLE